NEPHROPLUS
NEPHROCARE HEALTH SERV L
Each stock's 10,000-path forecast, rendered as light.
NEPHROCARE HEALTH SERV L (NEPHROPLUS) Stock Analysis & Case Study
Is NEPHROPLUS a good buy? The data-driven verdict.
NEPHROCARE HEALTH SERV L (NEPHROPLUS) trades at ₹724,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 28/100.
On the numbers, NEPHROCARE HEALTH SERV L (NEPHROPLUS) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 94.6× earnings, ROE of 9.1%, a 96% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
NEPHROPLUS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is NEPHROPLUS overvalued? NEPHROPLUS P/E vs its sector
NEPHROPLUS's P/E of 94.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers.
NEPHROPLUS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 0.5y of NEPHROPLUS history (90%/yr drift, 45%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| NEPHROPLUS 2027 | ₹910 | ₹1,624 | ₹2,918 | +121% |
| NEPHROPLUS 2028 | ₹1,610 | ₹3,619 | ₹8,222 | +393% |
| NEPHROPLUS 2029 | ₹3,037 | ₹8,043 | ₹22,009 | +996% |
| NEPHROPLUS 2030 | ₹5,634 | ₹17,771 | ₹57,371 | +2322% |
| NEPHROPLUS 2031 | ₹11,037 | ₹39,084 | ₹1,42,949 | +5227% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability NEPHROPLUS goes up, or doubles?
The bull case for NEPHROPLUS
- A 10,000-path probability model puts a 96% chance the price is higher in a year, with a median target of ₹1,624 (+121%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹22,009.
The bear case & risks
- A rich 94.6× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 9.1%, capital efficiency trails higher-quality peers.
- A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.
- High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹3,037.
NEPHROPLUS volatility & expected range, how bumpy is the ride?
Over the last 0.5 years NEPHROPLUS compounded at 90%/year with annualized volatility of 45%. That volatility implies a 1-year 80% range of ₹910–₹2,918, the honest backbone behind any single price target.
NEPHROPLUS price forecast, the full 60-month probability fan
NEPHROPLUS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds NEPHROPLUS hits common targets within the simulated horizon?
Full multi-horizon detail on the NEPHROPLUS price target & forecast page.
NEPHROPLUS Piotroski F-Score: 3/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. NEPHROPLUS scores 3/9,weak on the financial-strength checks.
NEPHROPLUS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy NEPHROPLUS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 30.2% | 3.3× |
| DhanCHEAPEST | 30.2% | 3.3× |
Compare every broker on the NEPHROPLUS MTF page.
NEPHROPLUS vs peers,sector comparison
About NEPHROCARE HEALTH SERV L: sector, index & market-cap context
NEPHROCARE HEALTH SERV L (NEPHROPLUS) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹7,267 Cr. See more Nifty 500 stocks.
How the NEPHROPLUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of NEPHROCARE HEALTH SERV L's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
NEPHROPLUS analysis, FAQs
Is NEPHROCARE HEALTH SERV L (NEPHROPLUS) a good buy?
On the numbers, NEPHROCARE HEALTH SERV L (NEPHROPLUS) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 94.6× earnings, ROE of 9.1%, a 96% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is NEPHROPLUS overvalued or undervalued?
NEPHROPLUS trades at 94.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the NEPHROPLUS share price target for 2031?
NEPHROPLUS's probability-weighted 2031 median target is ₹39,084, with an 80% range of ₹11,037–₹1,42,949 (10,000-path Monte-Carlo).
What is the probability NEPHROPLUS doubles in 5 years?
The modelled probability of NEPHROPLUS reaching ₹1,468 (2×) within 5 years is 100%.
What is the bull case for NEPHROPLUS?
A 10,000-path probability model puts a 96% chance the price is higher in a year, with a median target of ₹1,624 (+121%).
What are the risks in NEPHROPLUS?
A rich 94.6× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 9.1%, capital efficiency trails higher-quality peers. A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.